Celgene (CELG) PT Lowered to $91 at Goldman Sachs

January 27, 2017 5:44 AM EST Send to a Friend
Goldman Sachs lowered its price target on Celgene (NASDAQ: CELG) to $91.00 (from $96.00) while maintaining a Sell rating.Analyst Terence ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login